Level B· Emerging clinical evidence with positive signalsClinical TrialPubMedOpen access

Effect of Age, Harvest Site, and Body Mass Index on the Cell Composition of the Stromal Vascular Fraction.

Yang ZH., Zhang TY., Chen FZ., Xie Y., Tan PC., Li QF.

Clinical Trial with a reported sample of 162 on Hip, published in Plast Reconstr Surg (2025) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Plast Reconstr Surg (2025)
Country
United States
Reported sample size
162
Source database
PubMed
PMID
39840818
PMCID
PMC12288887
DOI
10.1097/PRS.0000000000011970
Citations
3

Abstract (original English)

Background The stromal vascular fraction (SVF) of adipose tissue has now been widely used in plastic surgery operations, clinical trials, and therapies. However, the cell composition of SVF undergoes dynamic changes during aging and obesity, which may influence the efficacy of the SVF. This study analyzed the effects of age, harvest site, and body mass index on the cell composition of the SVF. Methods A study was performed on 162 patients. The age ranged from 13 to 88 years old, with body mass index (BMI) less than 25 kg/m 2 or greater than or equal to 25 kg/m 2 . Fat tissue was harvested from the abdominal region, hips, thighs, or arms, and the SVF was isolated for flow cytometry. Results The authors' results demonstrated that the declines of adipose-derived stem cells (ADSCs) and endothelial cells (ECs) first occurred in donors aged 40 to 49 years. Subsequently, the percentages of endothelial progenitor cells, preadipocytes, and M2 macrophages started to decrease in donors aged 50 to 69 years. Lower percentages of ECs and M2 macrophages were found in donors with a higher BMI. Conclusions This study demonstrated that the percentages of ADSCs and ECs of SVF decreased significantly starting from donors older than 40 years, followed by changes in other cell subpopulations. Furthermore, donors with a BMI greater than or equal to 25 kg/m 2 had lower percentages of ECs and M2 macrop

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
HumansMiddle AgedBody Mass IndexAgedAdultFemaleMaleAged, 80 and overYoung AdultAdolescent

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research